Anti-vascular endothelial growth factor for myopic choroidal neovascularization


  • Conflict/competing interest: No stated conflict of interest.

  • Funding sources: No stated funding sources.

Dr Alvin K Kwok, Department of Ophthalmology, Hong Kong Sanatorium and Hospital, 5/F, Central Block 2 Village Road, Happy Valley, Hong Kong. Email:


Myopic choroidal neovascularization (CNV) is a vision-threatening complication in the eyes with pathological myopia, which is particularly prevalent among young and middle-aged Asians globally. To date, the verteporfin in photodynamic therapy study is the only randomized-controlled study in treatment of subfoveal myopic CNV. However, its long-term benefit is controversial. Recently, intravitreal injections of anti-vascular endothelial growth factors have shown promising results. In the absence of randomized-controlled trial comparing the efficacy of anti-vascular endothelial growth factors with photodynamic therapy and placebo, the purpose of this article is to review the current studies on functional and anatomical outcomes in both subfoveal and juxtafoveal myopic CNV. Furthermore, the influences of various doses and frequencies, as well as age and previous photodynamic therapy treatment on its effect are described.